Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
French biotech developer Defymed said today it inked a collaborative deal with American biotech company Semma Therapeutics to support the continued development of a bio-artificial pancreas to treat type-1 diabetes.
The collaborative deal will aim to achieve pre-clinical validation of Defymed’s Mailpan bio-artificial pancreas in combination with Semma’s stem-cell derived differentiated insulin-secreting cells, Defymed said. Read more
Nevro Corp. said last Friday that it received notice that Boston Scientific and its Neuromodulation division have filed a patent infringement suit against Nevro.
The suit, filed in The United States District Court for the District of Delaware, claims Nevro’s Senza neuromodulation system infringes upon Boston Scientific patents covering stimulation leads, batteries and telemetry unit. Read more
Echo Therapeutics this week announced a court ruling in its favor, denying a restrictive injunction and giving the company breathing room after it said last week that a long defense could drain its coffers and leave its future uncertain.
The company was facing a case in the U.S. District Court for Southern New York related to “various violations of the securities laws, theft of trade secrets, breach of contract and breach of fiduciary duty,” which on Friday was denied, according to a press release. Read more
Endologix said yesterday that the CE Mark approval of its AFX abdominal aortic aneurysm system will be suspended over reports of type III endoleaks with a previous-gen version of the device.
The AFX system is designed to provide anatomical fixation to treat a wide range of AAA anatomies, according to the company. Read more
Boston Scientific said today it closed its acquisition of manufacturing assets from Neovasc‘s advanced biological tissue business, as well as picking up a 15% equity investment in the company, spending a total of $75 million on both.
With the completed acquisition, Marlborough, Mass.-based Boston Scientific said it will integrate certain manufacturing assets and biologic tissue capabilities into its structural heart business, for use in manufacturing its Lotus valve and future heart valve technologies. Read more